Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen: Evidence Review Group's (ERG) additional analysis

The ERG has been asked to characterise the uncertainty around the extension to mean survival with enzalutamide treatment by providing 95% confidence intervals for the estimates of life years gained produced by the economic model. The results of this additional analysis are presented in the table below.

Table 1 – Mean overall survival in years as for the Committee's preferred scenario (section 4.15 of the ACD)

	Total population			Two or more prior chemo subgroup		
	Enzalutamide	BSC	Abiraterone	Enzalutamide	BSC	Abiraterone
Deterministic						
LYG	[redacted]	[redacted]	[redacted]	1.428	1.113	1.330
Difference*	[redacted]	[redacted]	[redacted]	-	0.315	0.098
Probabilistic						
LYG	[redacted] (95%CI: [redacted])	[redacted] (95%CI: [redacted])	[redacted] (95%CI: [redacted])	1.434 (95%CI: 1.162 - 1.767)	1.114 (95%CI: 1.026 - 1.209)	1.332 (95%CI: 1.174 - 1.514)
Difference*	[redacted] (95%CI: [redacted])		[redacted] (95%CI: -[redacted])		0.32 (95%CI: 0.075 - 0.617)	0.102 (95%CI: -0.175 - 0.41)

*Compared with Enzalutamide; BSC – Best Supportive Care